{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dental-abscess/goals-outcome-measures/qipp-options-for-local-implementation/","result":{"pageContext":{"chapter":{"id":"e9cfdeb1-ec38-5e0d-b03e-0acd118058b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation","depth":2,"htmlHeader":"<!-- begin field 8d650760-3d69-4594-a3ac-0d064d770f2d --><h2>QIPP - Options for local implementation</h2><!-- end field 8d650760-3d69-4594-a3ac-0d064d770f2d -->","summary":null,"htmlStringContent":"<!-- begin item 668be798-07ac-4c0c-9c05-4dd1d3b444f8 --><!-- begin field 3b25204f-6c94-4851-9463-70ccdd2968de --><ul><li><strong>Non-steroidal anti-inflammatory drugs (NSAIDs)</strong><ul><li>Review the appropriateness of NSAID prescribing widely and on a routine basis, especially in people who are at higher risk of gastrointestinal (GI), renal, and cardiovascular (CV) morbidity and mortality (for example older people).</li><li>If an NSAID is needed, use ibuprofen (1200 mg per day or less) or naproxen (1000 mg per day or less). Use the lowest effective dose and the shortest duration of treatment necessary to control symptoms.</li><li>Co-prescribe a proton pump inhibitor (PPI) with NSAIDs for people who have osteoarthritis or rheumatoid arthritis, and think about the use of gastroprotective treatment when prescribing NSAIDs for low back pain.</li></ul></li><li><strong>Antibiotic stewardship: prescribing antibiotics</strong><ul><li>Antibiotic resistance poses a significant threat to public health, especially because antibiotics underpin routine medical practice.</li><li>Review and, if appropriate, revise prescribing and local policies that relate to antimicrobial stewardship to ensure these are in line with the NICE guideline on <em>Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use</em>. A guideline on <em>Antimicrobial stewardship: changing risk-related behaviours in the general population</em> is in development (publication expected January 2017).</li><li>Review and, if appropriate, optimise current prescribing practice and use implementation techniques to ensure prescribing is in line with Public Health England (PHE) guidance on managing common infections, the Department of Health's guidance<em> Start smart — then focus</em>, local trust antimicrobial guidelines, and the Antimicrobial Stewardship in Primary Care collaboration TARGET antibiotics toolkit.</li><li>Review the following against local and national prescribing criteria:<ul><li>Total volume of antibiotic prescribing</li><li>Prescribing of quinolones, cephalosporins, co-amoxiclav, and other broad-spectrum antibiotics</li><li>Prescribing of 3-day courses of trimethoprim, nitrofurantoin, and pivmecillinam.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">NICE, 2017</a>]</p><!-- end field 3b25204f-6c94-4851-9463-70ccdd2968de --><!-- end item 668be798-07ac-4c0c-9c05-4dd1d3b444f8 -->","topic":{"id":"d9ce8bcf-6a30-56c3-9028-f291f9b80333","topicId":"7e8f6d78-0b6f-4813-baa8-3184010dd768","topicName":"Dental abscess","slug":"dental-abscess","lastRevised":"Last revised in October 2018","chapters":[{"id":"82801101-5e68-547d-8c3c-4ad6ec3b91b9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"92e4cbdc-7fa7-574b-bb17-97199587fe2d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e4034c8e-5cd0-5dc4-ba1d-f3ca1fe09c21","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84291395-fd80-58ef-a144-855cbf9b7b46","slug":"changes","fullItemName":"Changes"},{"id":"07b47e29-f600-5771-917c-4d6cd9135ed2","slug":"update","fullItemName":"Update"}]},{"id":"e967b353-dcf8-5e71-a9b0-95ca162918b8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"244fc23b-f275-5565-b50c-dca750baa8d9","slug":"goals","fullItemName":"Goals"},{"id":"1eb55d27-8795-5d81-8b81-4b4b6b7efa18","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2423d7f3-a323-50a3-8bbd-9664897bccd4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f5780547-92b5-5ede-a620-c7cf34a41b3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e9cfdeb1-ec38-5e0d-b03e-0acd118058b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"fa0115e4-0051-5374-8fae-1e1fbec27b97","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5f20011b-3e94-5351-a2a6-2a9565c42d7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69b7a1cd-7d22-52ab-b602-3a0c4bfbb4d4","slug":"definition","fullItemName":"Definition"},{"id":"617d13f2-34cd-5fd2-8869-198c3a3d5f06","slug":"causes","fullItemName":"Causes"},{"id":"777f9b6b-175c-5308-bba6-916d89e075b3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"cf5def0d-1ffd-5d57-b788-273fc8248d5c","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"735fc661-47ce-5a94-a29f-f0076c17ce88","slug":"complications","fullItemName":"Complications"}]},{"id":"df647f07-2727-5ac9-b87c-5adcdcf79bd6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b2a41850-a8dc-5b90-a7c5-4f2216c54cd2","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d97daa33-59c0-5607-a1fe-03238b7b333f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"6b0a689b-1ec7-5794-a5f0-b4efc84acfd2","fullItemName":"Management","slug":"management","subChapters":[{"id":"e6487762-ae28-5710-865a-01603c95176a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86cee72a-afc7-5150-92f0-6ff0e90b0172","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a9ed2df0-8168-51d7-b8e8-f5bb7c662d36","slug":"analgesics","fullItemName":"Analgesics"},{"id":"c8a5d71d-6f87-5315-aa1f-59791511dafe","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9bd34406-b8a3-5ab1-8a5d-3bd78925ef32","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"03d761c0-a760-5547-8910-97a65535bf94","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"91946ef3-8703-52eb-ba0a-b9cabca622e5","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"}]},{"id":"9c1469e7-dbca-5eaa-b2cd-29e127addf9a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aac7c7e4-eb79-5922-8ea7-3250adfae6b3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5aabd034-b3df-5bf4-93c1-30787cb35e17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6420441b-a18d-5bdb-a114-17409f623a23","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"65e26e16-4508-5e81-a8bf-307836e310cd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0aba46be-7078-5b8a-8557-56574cc69291","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2d089d7b-e753-518e-95f6-04243be55427","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f724f89d-9d85-5d8b-9675-d551cbf4aa5e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e967b353-dcf8-5e71-a9b0-95ca162918b8","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}